The legal action concerns investors who purchased securities between November 25, 2025, and May 4, 2026. According to the complaint, Embecta executives repeatedly reaffirmed revenue guidance and touted strength in the company’s pen needle segment, despite underlying business weaknesses. This optimism collapsed when the firm reported a failure to meet second-quarter projections and subsequently lowered its full-year outlook by 46%. The fallout included a 93% reduction in the company's dividend.

Shareholders who incurred losses during the designated class period have until August 17, 2026, to file papers with the court if they wish to serve as lead plaintiff. Robbins LLP is managing the litigation on a contingency fee basis, meaning participants do not incur out-of-pocket expenses for the legal representation. Those who choose not to join the proceedings remain eligible for potential recovery as absent class members.